Month: May 2022

– Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 – – Phase 2 expansion study of CX-2029 ongoing, patient enrollment completed for squamous non-small cell lung cancer cohort with data update expected in second half of 2022 – – First-in-human Phase 1 study of CX-904 in advanced solid tumors launching in first half of 2022 – SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported first quarter 2022 financial results and provided a business update. “The CytomX team continued to execute across our portfolio during the first quarter of 2022, including...

Niche Industrial and Branded Consumer Net Sales Growth Drive Record First Quarter Results Raises Full-Year Outlook Given Strong Q1 Performance WESTPORT, Conn., May 05, 2022 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the Company”), an owner of leading middle market businesses, announced today its consolidated operating results for the three months ended March 31, 2022. “CODI delivered outstanding first quarter results, recording our fifth consecutive quarter of record financial performance that is enabling us to raise our 2022 outlook,” said Elias Sabo, CEO of Compass Diversified. “Despite supply chain challenges and a heightened inflationary environment, our operating teams delivered double-digit sales growth in both our branded consumer and niche industrial businesses. In addition, we produced the highest level...

SAN FRANCISCO, May 05, 2022 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the second quarter of fiscal 2022. For the second quarter, Dolby reported total revenue of $334.4 million, compared to $319.6 million for the second quarter of fiscal 2021. “We feel confident about our long term growth opportunities despite near term headwinds,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “Our partners continue to enable a growing number of Dolby Vision and Dolby Atmos experiences through content and devices, and we are expanding our business with new immersive experiences through Dolby.io.” Second quarter GAAP net income was $36.7 million, or $0.36 per diluted share, compared to GAAP net income of $76.2 million, or $0.73 per diluted share,...

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights:Revenue was $81.6 million, compared to $66.7 million in the first quarter of 2021, representing growth of 22% over the first quarter of 2021. Excluding Pinnacle 21, revenue was $75.6 million, representing growth of 13% over the first quarter of 2021.   Net income was $2.2 million, compared to net income of $1.1 million in the first quarter of 2021, representing growth of 110% over the first quarter of 2021. Adjusted EBITDA was $27.7 million, compared to $23.9 million in the first quarter of 2021, representing growth of 16% over the first quarter of 2021.“Certara delivered strong revenue growth in the first quarter,...

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022. “We continue to preserve cash while actively pursuing new development or commercial-stage assets for Idera’s portfolio,” stated Vincent Milano, Idera’s Chief Executive Officer. “We also continue to work with JMP Securities, a Citizens Company, our current partner and advisor on business development activities, to explore additional strategic alternatives for the Company.”   First Quarter Financial Results Our cash position as of March 31, 2022 was $28.0 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period...

Q3 Total revenue of $122.6 million, an increase of 23% year-over-yearRaises FY’22 revenue guidance to $421-$422 million, an increase of approximately 20% year-over-year at the top end of the rangeCINCINNATI, May 05, 2022 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (“HCM”) software, today announced financial results for the third quarter of fiscal year 2022, which ended March 31, 2022. “Paycor delivered impressive revenue growth of 23% year-over-year, fueled by continued strong client growth,” said Raul Villar, Jr., Chief Executive Officer of Paycor. “Demand remains robust for modern cloud-based HCM solutions and our differentiated platform purpose-built for leaders and configured by industry continues to resonate in the market.” “We further enhanced our HCM...

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022 On track to initiate Phase 1b clinical trial of ALRN-6924 in patients with p53-mutated ER+/HER2- neoadjuvant breast cancer in 2Q 2022; initial interim results anticipated in 4Q 2022 Company to host a virtual investor event on May 19th to discuss ALRN-6924’s revolutionary potential as the first precision medicine-based supportive care drug, the landscape of chemotherapy-induced toxicities, and the company’s planned 2022 data readouts Cash, cash equivalents, and investments as of March 31, 2022, expected to fund operations into the fourth quarter of 2023BOSTON, May 05, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN),...

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company and a majority-owned subsidiary of Cellectis, released today financial results for Calyxt’s first quarter ended March 31, 2022. The contents of Calyxt’s announcement are included below. “The first quarter of 2022 marked a period of instrumental advancement across several critical areas for Calyxt. As a result of our expanded customer engagement, the breadth and depth of our business development discussions have grown, demonstrated by the 28 molecules identified by potential customers that we have evaluated for...